AB Science announces that FDA clears masitinib IND in Amyotrophic Lateral Sclerosis (ALS), allowing U.S. patient enrollment to commence in Phase 3 study

Ads

You May Also Like

IBA SA : IBA annonce ses résultats annuels consolidés pour 2017

IBA annonce ses résultats annuels consolidés pour 2017 Louvain-La-Neuve, Belgique, 22 mars, 2018 - IBA ...

Athersys and HEALIOS Announce Binding Letter of Intent to Expand MultiStem® Collaboration

Equity investment and binding letter of intent outlines expansion of Japan collaboration, including exclusive ...

TESARO Announces Updates to the U.S. Prescribing Information for VARUBI® (rolapitant) Injectable Emulsion

WALTHAM, Mass., Jan. 12, 2018 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical ...